Results 151 to 160 of about 5,950 (190)

Clinical and pharmacovigilance safety evaluation of LUXTURNA^® (voretigene neparvovec-rzyl). [PDF]

Cutan Ocul Toxicol
Simoens D, Shravah V, Jones WK, Kaja S.
europepmc   +1 more source

Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs. [PDF]

J Vet Pharmacol Ther
Nederveld SM, Krautmann MJ, Mitchell J.
europepmc   +1 more source

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. [PDF]

Headache
Nikitina V, Santi Laurini G, Montanaro N, Motola D.   +3 more
europepmc   +1 more source

Re-emergence of COVID-19 and preparedness.

Indian J Pharmacol
Choudhary G, Rajput H, Medhi B.
europepmc   +1 more source

Systematic Review of Active Safety Surveillance of Vaccines and Medicines in Low- and Middle-Income Countries. [PDF]

Drug Saf
Stergachis A, Sevene E, Alam MGS, Chandler RE, Precioso A, Mudigonda S, Nordenberg D, Chen RT.   +7 more
europepmc   +1 more source

Methodological and regulatory considerations for causal AI in drug development. [PDF]

NPJ Digit Med
Lee H, Qiu S, Haupert S, Innes GK, Naumann T, Alemayehu D, van der Laan M.   +6 more
europepmc   +1 more source

Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. [PDF]

Gut
Tseng CH, Wong S, Yu J, Lee YY, Terauchi J, Lai HC, Luo JC, Kao CY, Yu SL, Liou JM, Wu DC, Hou MC, Wu MS, Wu JJ, Sung JJY, El-Omar EM, Wu CY.   +16 more
europepmc   +1 more source

Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis. [PDF]

Lupus Sci Med
Li H, Xie W, Wang C, Guo C.
europepmc   +1 more source

Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.

Vaccine
Ibarz-Pavon AB, Bielsky MC, Bose R, Cavaleri M, Crump JA, Hombach J, Kaslow DC, Khaman F, MacLennan CA, Mehring-LeDoare K, Pollard AJ, Quadri F, John J, Wilder-Smith A.   +13 more
europepmc   +1 more source

WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever- key considerations and research gaps. [PDF]

Gates Open Res
Ibarz Pavon AB, Clemens J, Craviotto A, Crump JA, Garrett DO, Gordon MA, John J, Keddy KH, Laurens MB, Liu X, Marks F, Pollard AJ, Saha S, Wilder-Smith A.   +13 more
europepmc   +1 more source